Skip to main content

Day: August 19, 2024

Calibre Scientific Acquires Industrial Glassware, a U.S. Manufacturer and Provider of Laboratory Supplies and Consumables

Written by Customer Service on . Posted in Mergers And Acquisitions.

LOS ANGELES, Aug. 19, 2024 (GLOBE NEWSWIRE) — Calibre Scientific is pleased to announce the acquisition of Industrial Glassware (the “Company”), a U.S.-based manufacturer of caps, glass vials, glass and plastic bottles, jars, and provider of other related laboratory consumables used in the chemical, environmental laboratory, and industrial end markets. The acquisition of Industrial Glassware enhances Calibre Scientific’s U.S. manufacturing operations and expands its global portfolio of laboratory-related consumables. Founded in 1988, Industrial Glassware has supplied the North American market for over 35 years and has built up a strong reputation in the market and long-standing client relationships. The Company is well positioned in the market as a provider of high-quality containers for the environmental industry as well as caps...

Continue reading

Correction: Form 8.3 – Amendment International Distribution Services Plc

Written by Customer Service on . Posted in Mergers And Acquisitions.

FORM 8.3 AMENDMENTPUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Jupiter Fund Management Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of Offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree International Distributions Services plc(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date dealing undertaken:        For...

Continue reading

Tonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Highlights

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

On track to submit NDA in second half 2024 for TNX-102 SL for fibromyalgia; completed successful pre-NDA meetings with FDA in second quarter 2024 FDA granted Fast Track designation for TNX-102 SL for fibromyalgia Commercial planning continues for U.S. launch of TNX-102 SL, a potential new first-line, centrally-acting, non-opioid analgesic for the management of fibromyalgia U.S. Department of Defense contract awarded for up to $34 million over 5 years to develop a broad-spectrum antiviral drug World Health Organization (WHO) recently declared spread of mpox in multiple African countries a public health emergency of international concern – Tonix’s TNX-801 is an mpox vaccine in development which protects animals against lethal challenge of monkeypox virus CHATHAM, N.J., Aug. 19, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding...

Continue reading

CN Issues Lockout Notice to Teamsters

Written by Customer Service on . Posted in Public Companies.

Railroad Continues to Safely Shutdown Canadian Rail Network as Parties Remain Far Apart MONTREAL, Aug. 18, 2024 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) has issued notice to the Teamsters Canada Rail Conference (TCRC) formally advising them of its intention to lockout Canadian TCRC-represented employees on Aug. 22 at 00:01 ET unless an agreement or binding arbitration is achieved before that time. Despite negotiations over the weekend, no meaningful progress has occurred, and the parties remain very far apart. Unless there is an immediate and definite resolution to the labour conflict, CN will have no choice but to continue the phased and progressive shutdown of its network which would culminate in a lockout. CN must continue with the progressive and planned shutdown of its network, as we remain under the threat of an unpredictable...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.